Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy
Clin Nucl Med. 2024 Feb 7. doi: 10.1097/RLU.0000000000005084. Online ahead of print.ABSTRACTA 78-year-old man receiving bicalutamide for prostate cancer was referred for a PSMA PET/CT scan to evaluate his gradually rising prostate-specific antigen level. The PSMA PET/CT revealed gynecomastia with radiotracer uptake in bilateral breast parenchyma, a known but rarely reported effect of bicalutamide monotherapy. This scan also demonstrated metastatic progression of his disease in bone and lymph nodes, and he was started on leuprolide injections. Three months after a decrease in his testosterone level, the radiotracer uptake i...
Source: Clinical Prostate Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Miguel Muniz Daniel S Childs Jacob J Orme Geoffrey B Johnson Oliver Sartor Source Type: research
Intense 18F-Prostate-Specific Membrane Antigen Uptake and Mild 18F-FDG Uptake in a Biopsy-Proven Pulmonary Hemangioma
We present intense radiotracer activity in a soft tissue density abutting the aortic arch of the left lung on 18F-prostate-specific membrane antigen PET/CT scan in a patient with prostate cancer, mimicking metastatic disease from prostate cancer versus primary lung malignancy. 18F-FDG PET/CT scan, however, shows no elevated FDG activity. The results of pathology examination from resected specimen are consistent with pulmonary hemangioma.PMID:38377395 | DOI:10.1097/RLU.0000000000005117 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Feng Xu Frank Liu Source Type: research
Early Experience With Two-Fraction Spine Stereotactic Body Radiation Therapy in Treating Spinal Metastases
CONCLUSIONS: These findings suggest that 2-fraction spine SBRT is safe and effective, consistent with existing Level I evidence. Our local control rate exceeding 95% aligns with the literature, indicating the feasibility and achievability of implementing this approach in the United States over a short period of time.PMID:38372269 | DOI:10.1097/COC.0000000000001091 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Ifeanyi O Ekpunobi Shearwood McClelland Source Type: research
Macroscopy of specimens from the genitourinary system
J Clin Pathol. 2024 Feb 19;77(3):177-183. doi: 10.1136/jcp-2023-208831.ABSTRACTMacroscopic specimen examination is often critical for accurate histopathology reporting but has generally received insufficient attention and may be delegated to inexperienced staff with limited guidance and supervision. This review discusses issues around macroscopic examination of some common urological specimens; highlighting findings that are critical for patient management and others that are clinically irrelevant. Macroscopic findings are of limited value in completely submitted radical prostatectomy specimens but may be critical in orchi...
Source: Clinical Prostate Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Murali Varma John Dormer Source Type: research
Early Experience With Two-Fraction Spine Stereotactic Body Radiation Therapy in Treating Spinal Metastases
CONCLUSIONS: These findings suggest that 2-fraction spine SBRT is safe and effective, consistent with existing Level I evidence. Our local control rate exceeding 95% aligns with the literature, indicating the feasibility and achievability of implementing this approach in the United States over a short period of time.PMID:38372269 | DOI:10.1097/COC.0000000000001091 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Ifeanyi O Ekpunobi Shearwood McClelland Source Type: research
Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection
CONCLUSION: High comorbidity burden was associated with primary treatment choice, with significantly less RP and more EBRT, WW and ADT alone among men with higher levels of comorbidity. Each of the individual comorbid conditions also influenced treatment selection.PMID:38369388 | DOI:10.1016/j.clgc.2024.01.018 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 18, 2024 Category: Cancer & Oncology Authors: Tenaw Tiruye Michael O'Callaghan Liesel M FitzGerald Kim Moretti Alex Jay Braden Higgs Ganessan Kichenadasse Gillian Caughey David Roder Kerri Beckmann Source Type: research
Incidental Coronary Arterial Calcification for Cardiovascular Risk Assessment in Men With Prostate Cancer Undergoing PET/CT Imaging
CONCLUSIONS: MACE was common (21%) in men with recurrent prostate cancer undergoing PET/CT over 5 years of follow-up. Incidental coronary calcification on PET/CT was associated with increased risk of MACE and may have utility as a CV risk predictor that is feasible to implement among all prostate cancer providers.PMID:38369389 | DOI:10.1016/j.clgc.2024.01.014 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 18, 2024 Category: Cancer & Oncology Authors: Preet A Shaikh Avira Som Elena Deych Alison J Deng Melissa A Reimers Brian C Baumann Eric H Kim Daniel J Lenihan Kathleen W Zhang Source Type: research
A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer
CONCLUSIONS: The survival improvement reported by the IGCCCG Update Consortium is also operational in non-seminoma testis cancer patients within the most contemporary SEER database. This observation indicates that the survival improvement is not only applicable to centres of excellence, but also applies to other institutions at large.PMID:38369557 | DOI:10.1093/jjco/hyae011 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 18, 2024 Category: Cancer & Oncology Authors: Reha-Baris Incesu Simone Morra Lukas Scheipner Francesco Barletta Andrea Baudo Cristina Cano Garcia Stefano Tappero Mattia Luca Piccinelli Zhe Tian Fred Saad Shahrokh F Shariat Ottavio de Cobelli Carlo Terrone Felix K H Chun Luca Carmignani Alberto Brigan Source Type: research
Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories
Crit Rev Clin Lab Sci. 2024 Feb 15:1-23. doi: 10.1080/10408363.2024.2309935. Online ahead of print.ABSTRACTExtracellular vesicles (EVs) are nano-sized particles secreted by most cells. They transport different types of biomolecules (nucleic acids, proteins, and lipids) characteristic of their tissue or cellular origin that can mediate long-distance intercellular communication. In the case of cancer, EVs participate in tumor progression by modifying the tumor microenvironment, favoring immune tolerance and metastasis development. Consequently, EVs have great potential in liquid biopsy for cancer diagnosis, prognosis and fol...
Source: Clinical Prostate Cancer - February 16, 2024 Category: Cancer & Oncology Authors: Álvaro González Silvia L ópez-Borrego Amaia Sand úa Mar Vales-Gomez Estibaliz Alegre Source Type: research
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA
CONCLUSION: This external validation study confirmed previous results about modeled PSA longitudinal kinetics prognostic value regarding PFS/OS in patients with mCRPC treated with taxanes. PSA.KELIM could be used to identify a subpopulation with poor prognosis, who may benefit from treatment intensification.PMID:38364191 | DOI:10.1200/CCI.23.00208 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 16, 2024 Category: Cancer & Oncology Authors: Aurore Carrot St éphane Oudard Olivier Colomban Karim Fizazi Denis Maillet Oliver Sartor Gilles Freyer Benoit You Source Type: research
Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories
Crit Rev Clin Lab Sci. 2024 Feb 15:1-23. doi: 10.1080/10408363.2024.2309935. Online ahead of print.ABSTRACTExtracellular vesicles (EVs) are nano-sized particles secreted by most cells. They transport different types of biomolecules (nucleic acids, proteins, and lipids) characteristic of their tissue or cellular origin that can mediate long-distance intercellular communication. In the case of cancer, EVs participate in tumor progression by modifying the tumor microenvironment, favoring immune tolerance and metastasis development. Consequently, EVs have great potential in liquid biopsy for cancer diagnosis, prognosis and fol...
Source: Clinical Prostate Cancer - February 16, 2024 Category: Cancer & Oncology Authors: Álvaro González Silvia L ópez-Borrego Amaia Sand úa Mar Vales-Gomez Estibaliz Alegre Source Type: research
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA
CONCLUSION: This external validation study confirmed previous results about modeled PSA longitudinal kinetics prognostic value regarding PFS/OS in patients with mCRPC treated with taxanes. PSA.KELIM could be used to identify a subpopulation with poor prognosis, who may benefit from treatment intensification.PMID:38364191 | DOI:10.1200/CCI.23.00208 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 16, 2024 Category: Cancer & Oncology Authors: Aurore Carrot St éphane Oudard Olivier Colomban Karim Fizazi Denis Maillet Oliver Sartor Gilles Freyer Benoit You Source Type: research
Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories
Crit Rev Clin Lab Sci. 2024 Feb 15:1-23. doi: 10.1080/10408363.2024.2309935. Online ahead of print.ABSTRACTExtracellular vesicles (EVs) are nano-sized particles secreted by most cells. They transport different types of biomolecules (nucleic acids, proteins, and lipids) characteristic of their tissue or cellular origin that can mediate long-distance intercellular communication. In the case of cancer, EVs participate in tumor progression by modifying the tumor microenvironment, favoring immune tolerance and metastasis development. Consequently, EVs have great potential in liquid biopsy for cancer diagnosis, prognosis and fol...
Source: Clinical Prostate Cancer - February 16, 2024 Category: Cancer & Oncology Authors: Álvaro González Silvia L ópez-Borrego Amaia Sand úa Mar Vales-Gomez Estibaliz Alegre Source Type: research
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA
CONCLUSION: This external validation study confirmed previous results about modeled PSA longitudinal kinetics prognostic value regarding PFS/OS in patients with mCRPC treated with taxanes. PSA.KELIM could be used to identify a subpopulation with poor prognosis, who may benefit from treatment intensification.PMID:38364191 | DOI:10.1200/CCI.23.00208 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 16, 2024 Category: Cancer & Oncology Authors: Aurore Carrot St éphane Oudard Olivier Colomban Karim Fizazi Denis Maillet Oliver Sartor Gilles Freyer Benoit You Source Type: research
Adequacy of clinical guideline recommendations for patients with low-risk cancer managed with monitoring: Systematic review
CONCLUSION: With the exception of prostate cancer, the evidence base for monitoring low-risk cancer is weak and consequently recommendations in clinical guidelines are inconsistent. There is a lack of direct evidence to support monitoring recommendations in the literature making guideline developers reliant on expert opinion, alternative guidelines, or indirect or non-specific evidence.PMID:38360377 | DOI:10.1016/j.jclinepi.2024.111280 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 15, 2024 Category: Cancer & Oncology Authors: Kiana Collins Claire Friedemann Smith Tori Ford Nia Roberts Brian D Nicholson Jason Oke Source Type: research
